Free Trial

Benitec Biopharma Inc. (NASDAQ:BNTC) Receives $24.71 Average PT from Analysts

Benitec Biopharma logo with Medical background

Shares of Benitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) have received a consensus recommendation of "Buy" from the nine research firms that are covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $24.71.

Several research firms have recently weighed in on BNTC. HC Wainwright reissued a "buy" rating and issued a $28.00 price target on shares of Benitec Biopharma in a research note on Monday, March 24th. JMP Securities boosted their target price on Benitec Biopharma from $18.00 to $20.00 and gave the stock a "market outperform" rating in a report on Thursday, April 10th.

Read Our Latest Stock Report on BNTC

Benitec Biopharma Stock Performance

Benitec Biopharma stock traded up $0.31 during trading on Friday, reaching $14.05. The company had a trading volume of 7,730 shares, compared to its average volume of 40,997. The firm's 50-day simple moving average is $13.57 and its 200 day simple moving average is $11.91. The firm has a market capitalization of $329.49 million, a PE ratio of -9.30 and a beta of 0.34. Benitec Biopharma has a 1-year low of $5.74 and a 1-year high of $16.90.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last posted its quarterly earnings data on Friday, February 14th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.19. Analysts anticipate that Benitec Biopharma will post -1.48 EPS for the current year.

Insider Buying and Selling

In related news, Director Suvretta Capital Management, L bought 900,000 shares of the stock in a transaction on Wednesday, March 26th. The stock was bought at an average price of $13.00 per share, with a total value of $11,700,000.00. Following the completion of the purchase, the director now directly owns 8,793,245 shares in the company, valued at $114,312,185. This represents a 11.40 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Benitec Biopharma

Several large investors have recently made changes to their positions in the stock. Geode Capital Management LLC increased its holdings in Benitec Biopharma by 31.3% in the 3rd quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company's stock valued at $772,000 after purchasing an additional 20,012 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in shares of Benitec Biopharma by 134.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company's stock valued at $24,913,000 after buying an additional 1,131,129 shares during the period. MYDA Advisors LLC acquired a new position in Benitec Biopharma during the 4th quarter worth about $632,000. Franklin Resources Inc. lifted its stake in Benitec Biopharma by 269.0% during the 4th quarter. Franklin Resources Inc. now owns 2,939,287 shares of the biotechnology company's stock worth $37,123,000 after acquiring an additional 2,142,643 shares in the last quarter. Finally, 683 Capital Management LLC purchased a new position in Benitec Biopharma during the 4th quarter valued at about $452,000. 52.19% of the stock is currently owned by institutional investors and hedge funds.

About Benitec Biopharma

(Get Free Report

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.

See Also

Analyst Recommendations for Benitec Biopharma (NASDAQ:BNTC)

Should You Invest $1,000 in Benitec Biopharma Right Now?

Before you consider Benitec Biopharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.

While Benitec Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines